Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

JST Pang; N Shore; MR Smith; TL Tammela; A Ulys; E Vjaters; S Polyakov; M Jievaltas; M Luz; B Alekseev; I Kuss; MA Le Berre; A Snapir; T Sarapohja; K Fizazi

Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

JST Pang
, N Shore
, MR Smith
, TL Tammela
, A Ulys
, E Vjaters
, S Polyakov
, M Jievaltas
, M Luz
, B Alekseev
, I Kuss
, MA Le Berre
, A Snapir
, T Sarapohja
, K Fizazi

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Article number	201P
Number of pages	1
Journal	Annals of Oncology
Volume	30
Issue number	9 Suppl.
Publication status	Published - Nov 2019
Externally published	Yes
Event	European Society for Medical Oncology (ESMO) Asia Congress - Singapore, Singapore Duration: 22 Nov 2019 → 24 Nov 2019 https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Field of Science*

3.2 Clinical medicine
3.1 Basic medicine

Publication Type*

3.3. Publications in conference proceedings indexed in Web of Science and/or Scopus database

Access to Document

https://www.annalsofoncology.org/article/S0923-7534(19)57879-6/fulltext

Cite this

Pang, JST., Shore, N., Smith, MR., Tammela, TL., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., Alekseev, B., Kuss, I., Le Berre, MA., Snapir, A., Sarapohja, T., & Fizazi, K. (2019). Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial. Annals of Oncology, 30( 9 Suppl.), Article 201P. https://www.annalsofoncology.org/article/S0923-7534(19)57879-6/fulltext

@article{787f0367e0fc4b07ae8494b46c238f1d,

title = "Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial",

author = "JST Pang and N Shore and MR Smith and TL Tammela and A Ulys and E Vjaters and S Polyakov and M Jievaltas and M Luz and B Alekseev and I Kuss and \{Le Berre\}, MA and A Snapir and T Sarapohja and K Fizazi",

year = "2019",

month = nov,

language = "English",

volume = "30",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = " 9 Suppl.",

note = "European Society for Medical Oncology (ESMO) Asia Congress, ESMO ; Conference date: 22-11-2019 Through 24-11-2019",

url = "https://oncologypro.esmo.org/meeting-resources/esmo-asia-congress-2019",

}

Pang, JST, Shore, N, Smith, MR, Tammela, TL, Ulys, A, Vjaters, E, Polyakov, S, Jievaltas, M, Luz, M, Alekseev, B, Kuss, I, Le Berre, MA, Snapir, A, Sarapohja, T & Fizazi, K 2019, 'Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial', Annals of Oncology, vol. 30, no. 9 Suppl., 201P. <https://www.annalsofoncology.org/article/S0923-7534(19)57879-6/fulltext>

TY - JOUR

T1 - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

AU - Pang, JST

AU - Shore, N

AU - Smith, MR

AU - Tammela, TL

AU - Ulys, A

AU - Vjaters, E

AU - Polyakov, S

AU - Jievaltas, M

AU - Luz, M

AU - Alekseev, B

AU - Kuss, I

AU - Le Berre, MA

AU - Snapir, A

AU - Sarapohja, T

AU - Fizazi, K

PY - 2019/11

Y1 - 2019/11

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=rsu_pure_&SrcAuth=WosAPI&KeyUT=WOS:000503487700196&DestLinkType=FullRecord&DestApp=WOS

M3 - Meeting Abstract

SN - 0923-7534

VL - 30

JO - Annals of Oncology

JF - Annals of Oncology

IS - 9 Suppl.

M1 - 201P

T2 - European Society for Medical Oncology (ESMO) Asia Congress

Y2 - 22 November 2019 through 24 November 2019

ER -

Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

UN SDGs

Field of Science*

Publication Type*

Access to Document

Other files and links

Cite this